MoonLake Immunotherapeutics - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MLTX Nasdaq 2830 www.moonlaketx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MoonLake Immunotherapeutics

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - Jun 4th, 2025 10:06 am
Update: Market Chatter: Merck Held Talks to Buy MoonLake for Over $3 Billion; MoonLake Shares Rise - Jun 3rd, 2025 9:52 am
Constellation and Meta, Merck, Snowflake: Trending Tickers - Jun 3rd, 2025 7:33 am
MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid - Jun 3rd, 2025 7:27 am
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report - Jun 3rd, 2025 5:38 am
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports - Jun 2nd, 2025 3:08 pm
H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT - May 27th, 2025 1:33 pm
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet - May 15th, 2025 7:55 am
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update - May 12th, 2025 2:00 pm
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 - Apr 25th, 2025 2:05 pm
Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Apr 23rd, 2025 10:52 am
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates - Apr 3rd, 2025 5:00 am
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - Feb 26th, 2025 5:00 am
Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? - Feb 25th, 2025 7:49 am
MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts - Feb 23rd, 2025 11:33 am
MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now - Feb 20th, 2025 10:12 am
We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely - Feb 11th, 2025 3:19 am
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG - Jan 10th, 2025 5:15 am
MoonLake's Three New Trials Will Expand Sonelokimab's Potential, Wedbush Says - Jan 8th, 2025 9:53 am
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab - Jan 8th, 2025 5:00 am